Ad
Search
Generic filters
Filter by content type
Taxonomy terms

TCRX – TScan Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.8

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 14

Low: 6

High: 21

Total Analysts: 5

Company Profile

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company’s platform discovers anti-cancer TCRs from patients with responses to immunotherapy and also manufactures TCR-T therapies. It is also advancing five solid tumor programs: TSC-200, TSC-204, TSC-201, TSC-202, and TSC-203.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses